Cutaneous T-cell lymphoma (CTCL) is a group of lympho proliferative disorders characterized by localization of neoplastic T lymphocytes to the skin. Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL). Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma. More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. They often appear as eczema-like skin rashes and can affect widespread parts of the body. There are different subtypes of CTCL, mostly they are slow growing but some can be fast growing. The most common types of CTCL are Mycosis Fungoides and Sezary Syndrome
US Epidemiology Scenario –
Market Forecast till 2025 –
We have seen that the United States accounts for the highest incident population of CTCL than EU5 (Germany, France, Spain, Italy and UK) and Japan. There were approximately 3200 incident cases in 2016. According to Diligent Market, it is estimated that the incident cases of CTCL shall increase at a CAGR of 0.35% for the period 2013-2025
In 2013, there were 1703 cases of Mycosis Fungoides estimated in United States. The incident rate of Mycosis fungoides has been increasing significantly since 1970s. Other subtypes includes Sezary syndrome, Primary Cutaneous Peripheral T-cell Lymphoma, unspecified, ATLL, Primary Cutaneous CD30+ T-cell Lympho Proliferative disorders and Subcutaneous Panniculitis-like T-cell Lymphoma (SPTCL), which comprises of approximately XX% cases of total CTCL incident population.
Key Findings –
The treatment of CTCL depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The FDA approved drugs are Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex (methoxsalen), Targretin (bexarotene) and Zolinza (vorinostat).
Amongst all the 7MM, United States accounts for highest market share for CTCL due to high incidence as well as due to high annual cost of therapy. The total Cutaneous T-Cell Lymphoma market size in 7MM will increase at a compound annual growth rate (CAGR) of 1.6% for the forecasted period i.e., 2017-2025 and will reach 1.6 Billion by 2025
Early stage accounts higher market share of CTCL in comparison to the late stage. According to Diligent Market, it is estimated that the market size of early stage and late stage CTCL shall increase at a CAGR of 1.89% and 0.93% respectively from 2013 to 2025.